title: [The use of low-molecular heparins in prevention and treatment of thrombotic complications after radical prostatectomy].
abstract: Effects of low-molecular heparin flaxiparin on prevention of thrombotic complications after radical prostatectomy were studied in two groups of patients with localized forms of prostatic cancer at stages T1c, T2a, T2b and T3a. Group 1 received non-fractionated standard heparin in a dose 5000 units 4 times a day for 10 days. Group 2 was treated with flaxiparin in a dose 0.3 ml (7500 U anti-Xa) twice a day s.c. for 10 days. After therapy no thromboembolic complications were observed. In group 2 removal of the urethral catheter was conducted 4-5 days earlier than in group 1. This reduced hospital stay from 29 to 20 days. Flaxiparin accelerated growing vessels in the zone of urethrourethral or urethrovesical anastomosis resulting in improvement of microcirculation and preventing strictures in the anastomotic zone. Thus, low-molecular heparin prevents thromboembolic complications, reduces hospital stay and duration of rehabilitation after radical prostatectomy.
authors.forename: G G
authors.initials: GG
authors.lastname: Khomeriki
authors.forename: S P
authors.initials: SP
authors.lastname: Darenkov
authors.forename: E O
authors.initials: EO
authors.lastname: Osmolovskiĭ
authors.forename: D A
authors.initials: DA
authors.lastname: Okhobotov
mesh_terms: D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight